you, quarter our for joining Thank fourth of iQ current focus thank And us. state results, our my our and and I’m and to of today the our HFX everyone comments recovery, on the new the of afternoon, Julie. market going launch, business PDN limited System. progress release you good
QX, ‘XX comments, continue Overall, quarter Now will first guidance. positive cover our with specifics results year our and following Rod the to think of we QX and some I entering our and full we’re forward in real move my business ‘XX momentum.
at guidance, Our EBITDA one-time charges. revenue growth procedure end our adjusted results our the within and rates guidance was range, were high grew double-digits excluding of US
XX%. forward, our really and There currency attractive elements on our going gradually growth ‘XX improve came US in over basis, were to revenue that and throughout in beyond. the with Global year a will I’m place for while leverage revenue are in believe at number pleased challenges encouraging prior the fourth quarter. steadily growth XX% but market a of progress was the building growth now constant the of blocks and to continue
US growth. And X% activity delivered trial year-over-year
‘XX full comparable trials, course well. for was daily and reported qX, continue revenues QX of for last competitive quarter year which about period. to market all-time thus with In gain months XXXX on were in in of the October, trial rates far and Based ahead US share December fact, record in X% as US the our November pre-COVID we fact,
well AI-powered be on in more using in is from this positive PDN finally, release relief pain significant feedback regarding physicians of performing with market And growth Algorithm position driver throughout further limited new patients System this and and HFX my remarks, competitive really continues impressive later our to with technology our iQ really a quarter-over-quarter space. the ability personalized to XXXX. the I deliver performance differentiate iQ has to big opportunity in our think but our HFX data-backed
this course continue remain positioned SCS recent of superior continued the progress on our recovering addressable that we’re the as of fundamentals We that we’re to and confident ‘XX. and largely paresthesia-free believe the high-frequency intact. recede beginning for builds market opportunity market of our All for market growth signs and of well in challenges underlying see a technology we are to
to it’s see as pandemic the likely growth see ‘XX that the We starting the that it’s know in linear And – going to encouraging begin we by trials be we’re see unlikely of to rather to and wane. that permanent to is in though continue impacts nature. we recovery continue to think We the expected implants. that way throughout
we ‘XX Of throughout pressure these and fourth But seem procedures. believe will the trend course, lingering congestion staffing capacity challenges also continue improve to do as and of scheduling put a continue little this the on during well. quarter to
currency account takes guidance into on first for to Our quarter and a year-over-year revenue XX% implies basis. constant X% growth of the us
the sequential to usually Of assumes we this seasonality typical QX. course QX see from
we patient previous been growth pain return handle expect time specialists to has Our to that to capacity engagement improving. volumes more pre-COVID the markets historical is with fully over see indicated And CAGRs. research as restored, market
business. PDN our to now Turning
expectations platform continuing in referring to exceeded forward our clinical we’re this develop XXXX. XXXX, progress in with to looking exciting and clinicians, Our societies payers and growth
the of up US total total trial the from quarter, represented QX. of XX% our trials volume, quarter. of approximately And our that throughout US improved actually volume XX% in course that’s trial During PDN the
in quarter, in which and million XX% procedures, in sales. And implant PDN our in XX% indication around $XX.X organization $XX.X resulting million worldwide of outreach as PDN patients. with that’s the permanent an the sequentially, well compared measure that increase both expansion third in June to total represented attribute our initiatives approximately Among of we completed sales large that procedures was PDN referral as physicians the
trial and we new of programs DTC test our month to programs to media December, generated and and interests channels approximately directly. with continue the awareness procedures PDN patients by of from direct-to-patient In own our drive leads US XX% came
place the case-by-case coverage payer the including don’t for we through policies a payer physician who in to see existing policy. to coverage level positive appeal with continue and payers approvals process addition a of have In authorization or the denials, of PDN prior high a PDN, rather
our continue For up at that have XXXX. cases about end December the And come group, trend that from access the XX%. of our those PDN through was own XX% as of approval around of end rate to cumulative
Life improvement XX-month NANS durability Finally, These Dr. the as complete XX-months two podium relief of and Quality RCT were presented achieved in presentations by Petersen. function in PDN XX results data of pain of confirmed and neurological separate at the clinically the the kilohertz with in strong Erika quality data trial life well meaningful Conference RCT therapy. January as long-term
expect data coming months We publication. for submit the in this to
patient RCT of arm looking enrolling our first specifically new endpoint intractable quarter assess Sensory a first powered plan We forward also to will PDN. we’re our addition, neurological months with with enroll in conventional to function PDN criteria as six restoration In which be primary next study, the in prospective kilohertz be US, multiple plus patients across medical XX treatment optional the management, to management crossover to to if other medical sites to met. XXX those are at SCS the at or randomized patients conventional will up patients
staggering burden. option reasons. several is disease-modifying available for is really This Diabetes socioeconomic for pose groundbreaking PDN. peripheral and study There neuropathy patients no available Sensory with a treatment
ulcers preventable, course, amputations US In many are XX are Preservation lack Limb the of diabetes protective feet of to psychosocially. treatment to these surgeries associated And fact, patients amputation economically every according in related seconds foot contribute unrecognized sensation. numb insensate and also as and Society. both there’s But a American injuries costly, amputation and, the or
health with we evidence XXk and which our burden, the neurological and the costs. reduce kilohertz saw in course, sensory prevent intractable pain of disease-modifying forward with improving feet, RCT clinical benefits the in relief. XX this and pain SCS sensation study in targeting to all progression lower function, path and of amputations and landmark affords loss or alleviate study for patients improve limbs disease of active on to quality endpoints restoring the of outcomes significant powered slowing life would builds patients also SCS a chronic healthcare improved of building be may of This By enable more tremendous overall
unique recall are coverage SCS benefits the continue X that as reported Nevro’s for therapy SENZA-PDN modality. to You’ll be observed Not expand these But have anticipate we the been to of of in generally. generated confirmatory additional Level believe that PDN we payers very helpful not additional PDN the will original to XXk neurological also improvements study proprietary XXk with data saw only we in work will evidence patients. that we competitive provide other the SCS this study do and any
device FDA sensory FDA designation and designation has pleased to application the by expand earlier, quarter patient for This expedited that patient announce indication. to breakthrough an I’m potential target provides we’re and the really I opportunity PDN a enrolling review for for And forward study, device for look we granted about FDA the group. as excited next Nevro’s marketing this said labeling. our first to the this
in significant year. is be to for growth expected us progress a ‘XX, PDN this Following once our again strong driver
their one of of patients December of interest or planting practice. physicians as Nevro example XX% growing of the and another end PDN with over consulted PDN, As in in the had more
contribution million XX% PDN, guidance Our an a to from XX% ‘XX. increase million $XX that’s to over ‘XX includes of revenue $XX
as As SCS be going as perhaps of much spinal PDN significant the cord of the market. growing a one we US more we to time, said, third stimulation, over of is think to parts
‘XX in of this second for guidance implies business our XX% already will to year. patient a full own Our about segment XX% just be
January, patient Moving not of non-surgical existing of education access for the already a indication by practices, to surgery are began prior receiving pain, candidate this have pain identification not activities population last surgery. FDA who HFX approval and and expand therapy out this to after commercial had patients for who back focusing of on we at
of the tide entire population and Unlike PDN, always a for we’ve pain sort SCS industry NSBP the rising patient viewed that’s specialty.
was the year, indication. NANS to this NSBP also evidence of continue the but We lead our to began supporting generating data, it their data foundation charge see clinical to this report at build to competitors in helps encouraging own clinical which
therapy exhausted help SCS more competitors to patients for the SCS candidates. their to continue us As grow forwards in We generation market believe continue will back options these our who for NSBP pain believe of this coming cover all patients join therapy for have the will data, leg years. to other and we payers the in
positive chronic refractory at as as were well with significant life seen Speaking of investigators strong, in NANS, non-operative data had follow-up These spine surgical a which that, and for our patients medical and reported function pain clinical management. clinically by XXk improvement quality stable presented durable patients back surgeon a pain important included candidacy appropriate for results SCS two-year relief low our and SENZA-NSBP with who improvement. of trial treated all were in who exhausted in evaluated
the on which became UnitedHealthcare’s patients we’ve exclude impact On noticeable on today, reimbursement experienced not any X. coverage decision our to revenue NSBP from for front effective December
We generation evidence of high also a impact our don’t previously, PDN thus to the the it as we as on believe carry with opportunity said indication. material quality have decision far clinical coverage ultimately expect continued and revenue will we day this just has go-forward our
turn our System. to HFX new Now, to I’d iQ Senza like
cord we has and initiated smarter something spinal is well device interaction that stimulation iQ by from received. gets which learning been experience the each pain other patient’s and is market last therapy. by big no data. system US time, the very powered approval patient’s limited has the with quarter, over release iQ that system SCS first data-backed, FDA big Following AI-powered a
a of over from HFX fact, Cloud database. patient patient In decade longitudinal our data
to to personalize profile. based designed progress their starts XX data each product. to Our the and patient to in is patient therapy HFX based journey. relief individual a iQ their pain stimulation over the over on on is provide on relief specific XX,XXX app million Bluetooth-enabled program patient’s algorithm inputs this database Algorithm patients points from drives which the most patients likely iQ clinical along recommendations learns connected This and
more AI big and their engagement patients combination on direct giving data, and over outcomes our optimize and on based our data. control of individualized and maintain their and that supplement is relief them. both detailed experience pain suits This input team, intended patient summary pain relief a HFX to an a with field time powerful Coach’s is provides personal that iQ our database physicians to Cloud at basis and
larger way, in We will logical ‘XX us support this and beyond. our believe more patients the revenue is the prospects the to growth the growth, of customers more really and product the to I over team on the years. profitable iQ next and to our forward. drive patients By as Rica our with well revenue base a lessen scale existing going iQ it and ramp burden facility with this is effectively launch our growth help and Costa the up in us our to enables manufacturing step earnings allowing line coming of expect the combined going believe of productivity our
NANS At education HFX iQ we a well-attended our an to several exhibit launch. had Meeting, opportunity booth other feature the including System and the at physician events,
launch very meaningful the product and shift the rest to soon, We’re throughout a preparing for the of in full HFX expect a US year. mix iQ
already in addition submitted for and iQ, approval Australia. In to for US Europe the we’ve approval
We exciting chronic to it an of than as to indications it patients to technology. we’ve Nevro with the therapy, globally think new firmly and customers lives life pain. with our commitment technology, we with deliver what keeps patients. data bring HFX now the as solutions summary, iQ our patients new our impacted we’re of of In SCS more represents continued innovation our implanted the continue XXX,XXX for in comprehensive doing And and the changing future time comes new forefront and iQ at the reflects
to very Management of robust European this device applications mention recently the internal medical to the the several that preparation assessment regulatory certification by framework. And I’m regulatory European the to years it we MDR. of more received work should certification announce of follows team, regulatory received as certificate and of certification have that and We’re also undergone received a our pleased about XX% notified to according companies standard of only new new new strong first I Nevro wave bodies really by medical a strength was and device this validation EU standard. is that companies among for Quality our proud achieve and our System, This known to
So, for what our encouraging future the of recovery continued expense patient closing, attractive products intense the will as fourth focus structure. with markets, PDN HFX made And we on platform, the our entirely be opportunity in NSBP. populations of on in operating iQ growth and new our progress quarter like the believe we important a new result like in scalability leverage
Nevro for bright. think is I the increasingly outlook
guidance. on to the our Rod that, with and results And pass to I’ll call over fourth quarter provide further our on details
